For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Concerned that Health Economic Evaluation Will Be Used to Reduce NHI Prices: Mr Zulueta
February 6, 2012
- JACDS to Strengthen Support to Ensure Compliance in Sale of OTC Drugs
February 6, 2012
- It Is Difficult to Check Off-Label Use of Generics Approved for Indications Different from Those of Original Drugs: Medical Bill Payment Fund
February 1, 2012
- JPMA to Make Proposals on Pricing of Long-Listed Drugs to CSIMC: President Teshirogi
January 31, 2012
- BG Kansai to Establish Service Hub to Support Use of Supercomputers in Drug Discovery
January 31, 2012
- MHLW, JPWA Hold Public-Private Dialogue on Distribution Improvement
January 30, 2012
- JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
- JPA Supports Ban on “Dispensing Point” Services at Pharmacies
January 26, 2012
- JSMI to Seek Expansions of OTCs by Appealing Preventive Effects in 2012
January 24, 2012
- JPMA to Focus on Thorough Enforcement of Compliance in Next Fiscal Year
January 20, 2012
- JPMA to Discuss State of Long-Listed Products Over a Year Ahead of FY2014 Revision
January 19, 2012
- JPMA to Set Transparency Guideline for Relationships with Patient Organizations, Disclose Information from FY2013
January 19, 2012
- JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
- FPMAJ Detects Radioactive Substances in 2 Crude Raw Material Samples
January 17, 2012
- JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
- JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
- PMAT President Matsuda Says Permanent Introduction of Premium is Priority Issue
January 10, 2012
- FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
- New Year’s Remarks: We wish each of our stakeholders a very Happy and Healthy New Year 2012.
January 5, 2012
- 2012 New Year’s Message: The Ultimate Winner of the Medical Policy Changes is the Patient
January 5, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…